AC Immune SA announced positive interim safety and immunogenicity data from the Phase 2 VacSYn clinical trial evaluating ACI-7104.056, its wholly owned anti-alpha-synuclein active immunotherapy candidate. The trial is for the treatment of patients with early Parkinson’s disease.
Interim results demonstrated that treatment with ACI-7104.056 induced an increase in anti-alpha-synuclein antibodies on average 16-fold higher than the placebo background level after three immunizations. Furthermore, 100% of patients receiving ACI-7104.056 responded against the target antigen, indicating a robust immune response.
The therapy was well tolerated, with no clinically relevant safety issues reported to date, beyond transient injection site reactions in 49% of patients and headaches in 18%. ACI-7104.056 is one of two FDA Fast Track designated candidates in AC Immune's pipeline, highlighting its potential.
AC Immune anticipates sharing further updates in the first half of 2025, including pharmacodynamic data and a decision regarding the expansion into Part 2 of the VacSYn study. These results reinforce the potential of ACI-7104.056 as a best-in-class treatment for Parkinson's disease.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.